Skip to main content
. 2015 Jun 15;7:165–173. doi: 10.2147/CMAR.S61408

Table 2.

Best overall response in each treatment arm

Sunitinib + mFOLFOX6 (n=96) Bevacizumab + mFOLFOX6 (n=95)
Complete response, n (%) 1 (1.0) 1 (1.1)
Partial response, n (%) 38 (39.6) 35 (36.8)
Stable disease, n (%) 44 (45.8) 53 (55.8)
Progressive disease, n (%) 3 (3.1) 1 (1.1)